De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Anshan Hifichem Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Huixiang Xu

Algemeen directeur

CN¥797.2k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	18.3yrs
Eigendom CEO	15.8%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	7.8yrs

Recente managementupdates

Recent updates

Why Investors Shouldn't Be Surprised By Anshan Hifichem Co., Ltd.'s (SZSE:300758) 27% Share Price Surge

Oct 01

Anshan Hifichem (SZSE:300758) Has A Somewhat Strained Balance Sheet

Jul 26

There's Reason For Concern Over Anshan Hifichem Co., Ltd.'s (SZSE:300758) Massive 30% Price Jump

May 27

Anshan Hifichem (SZSE:300758) Could Be Struggling To Allocate Capital

May 06

With Anshan Hifichem Co., Ltd. (SZSE:300758) It Looks Like You'll Get What You Pay For

Feb 28

CEO

Huixiang Xu (53 yo)

18.3yrs

Tenure

CN¥797,219

Compensatie

Mr. Huixiang Xu serves as Chairman and General Manager of Anshan Hifichem Co., Ltd and has been its Director since June 12, 2006.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Huixiang Xu	Chairman & GM	18.3yrs	CN¥797.22k	15.81% CN¥ 824.2m
Zhi Qiao	Deputy GM & Non-Independent Director	5.4yrs	CN¥533.06k	0.25% CN¥ 13.1m
Xuebo Qi	Deputy GM & Director	18.3yrs	CN¥427.60k	0.46% CN¥ 24.0m
Zhidong Liu	Non-Employee Supervisor	9.4yrs	geen gegevens	0.061% CN¥ 3.2m
Dongbo Li	Staff Supervisor	13.2yrs	geen gegevens	0.0057% CN¥ 299.7k
Sukun Wang	Non-Employee Supervisor	6.4yrs	geen gegevens	0.13% CN¥ 6.7m
Zhiqun Zhang	Non-Independent Director	9.1yrs	CN¥370.67k	0.10% CN¥ 5.4m
Xiaodong Liang	Independent Director	3.3yrs	CN¥96.00k	geen gegevens
Wenyong Duan	Non-Independent Director	7.8yrs	geen gegevens	geen gegevens
Qi Wang	Independent Director	2yrs	CN¥96.00k	geen gegevens
Yonghua Wang	Independent Director	2yrs	CN¥96.00k	geen gegevens

7.8yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300758 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Anshan Hifichem Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024

Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024

Insufficient new directors

High number of new directors

Anshan Hifichem Co., Ltd. Announces Directorate Changes

High number of new directors

Recent updates

Why Investors Shouldn't Be Surprised By Anshan Hifichem Co., Ltd.'s (SZSE:300758) 27% Share Price Surge

New minor risk - Share price stability

Anshan Hifichem Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 31%

Anshan Hifichem Co., Ltd. Announces 2024 Interim Profit Distribution Plan (A Shares),Payable September 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.007 in 2Q 2023)

Anshan Hifichem (SZSE:300758) Has A Somewhat Strained Balance Sheet

Anshan Hifichem Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

There's Reason For Concern Over Anshan Hifichem Co., Ltd.'s (SZSE:300758) Massive 30% Price Jump

Anshan Hifichem (SZSE:300758) Could Be Struggling To Allocate Capital

First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.04 loss in 1Q 2023)

New major risk - Share price stability

Anshan Hifichem Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

With Anshan Hifichem Co., Ltd. (SZSE:300758) It Looks Like You'll Get What You Pay For

Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024

New minor risk - Share price stability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024

New major risk - Revenue and earnings growth

Anshan Hifichem Co., Ltd. to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.009 loss in 3Q 2022)

New minor risk - Share price stability

Anshan Hifichem Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.007 (vs CN¥0.002 in 2Q 2022)

First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.06 profit in 1Q 2022)

Insufficient new directors

High number of new directors

Third quarter 2022 earnings released: CN¥0.009 loss per share (vs CN¥0.094 profit in 3Q 2021)

Anshan Hifichem Co., Ltd. Announces Directorate Changes

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.002 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Anshan Hifichem Co., Ltd. Approves 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on May 26, 2022

Anshan Hifichem Co., Ltd. Approves Cash Dividend

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Anshan Hifichem Co., Ltd. Proposes Final Dividend for the Year 2021

Third quarter 2021 earnings released: EPS CN¥0.094 (vs CN¥0.12 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.28 in 2Q 2020)

Investor sentiment deteriorated over the past week

Anshan Hifichem Co., Ltd. (SZSE:300758) agreed to acquire additional 29% stake in Shaoxing Shangyu Xinli Chemical Industry Co., Ltd. from Chen Jianxin for approximately CNY 150 million.

Full year 2020 earnings released: EPS CN¥0.91 (vs CN¥0.59 in FY 2019)

New 90-day low: CN¥21.86

New 90-day low: CN¥23.42

Market bids up stock over the past week

New 90-day low: CN¥23.45

Third quarter earnings released

Market bids up stock over the past week

Earnings released

Anshan Hifichem Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd